Michael Mølhøj, Ph.D.

Vice President CMC Biologics

Michael Mølhøj joined Immatics in 2020 and heads the department of CMC Biologics. The department is responsible for all CMC aspects related to the pipeline of bispecific T-cell receptor engaging molecules (TCER®).

Michael brings 21+ years of Biotech/Pharma R&D experience (GLP/GMP) from leading developability assessments, process developments and analytical activities, to developing advanced bispecifics towards IND/IMPD submission and clinical testing. He has worked for Hoffmann-La Roche (Penzberg, Germany) as technical project leader of T-cell activating bispecific antibodies and mass spectrometry lab head. Prior to Roche, Michael worked for Micromet (now Amgen) and Scil Technology. He is a co-inventor of multiple patents and patent applications related to a range of therapeutic bispecific antibodies, bispecific antibody molecular formats, and analytical methods. Additionally, he has co-authored over 30 publications in international peer-reviewed journals.

Michael holds a Master’s degree and a Ph.D. from the Faculty of Life Sciences at the University of Copenhagen, Denmark.
A proud contributor to approved Faricimab (Vabysmo; VEGF-A-Ang2 CrossMab) and Glofitamab (Columvi; CD20-TCB).